Study on Using Biomarkers to Understand and Diagnose Neurological Diseases

What this Trial Is About

This research aims to explore the predictive and diagnostic roles of biomarkers in patients with neurological diseases. It focuses on using proteomics and metabolomics technologies to study brain tissue, plasma, and cerebrospinal fluid to identify potential new biomarkers. The study seeks to better understand biomarker expression in healthy individuals compared to those with neurological conditions and to address unresolved challenges in this early-stage research. Patients admitted to hospital or emergency departments with neurological diseases will be observed. Clinical data, laboratory data, imaging data, and blood and tissue samples will be collected at baseline and during follow-up at various time points in acute and chronic phases. This observational approach does not involve experimental treatments but gathers comprehensive information to support biomarker research. Participants will be monitored through clinical evaluations including a modified Rankin Scale score at 90 days. The study involves consented collection of samples without affecting patient diagnosis or treatment. Data will help researchers assess biomarker characteristics and their relation to disease progression and outcomes. The study is planned to continue until December 2031, allowing long-term follow-up and analysis.

Application of Biomarkers in Neurological Diseases